极低出生体重婴儿的早产儿视网膜病变与神经发育障碍的关联
该前瞻性队列研究基于韩国新生儿网络2013至2015年数据,纳入3132例极低出生体重儿,评估早产儿视网膜病变(ROP)严重程度及治疗方式与矫正年龄18至24个月神经发育障碍的关联。结果显示,需治疗的ROP组较无ROP组神经发育问题风险升高(OR=1.72,95%CI=1.33-2.21),而激光与抗VEGF治疗组间风险无显著差异(OR=1.17,95%CI=0.73-1.88)。
要点
- 需治疗的ROP与早期儿童神经发育障碍独立相关(OR=1.72,95%CI=1.33-2.21)。
- 需治疗ROP组精神、社交及运动发育问题风险均升高。
- 激光与抗VEGF治疗组神经发育问题风险无显著差异(OR=1.17,95%CI=0.73-1.88)。
核心结论
- ROP与早期儿童神经发育障碍独立相关。
- 在需治疗的ROP患者中,ROP治疗类型(抗VEGF或激光)未影响神经发育障碍。
研究设计与样本
- 前瞻性队列研究,数据来自韩国新生儿网络(KNN),为极低出生体重儿的全国性登记系统。
- 纳入2013年至2015年出生、并在矫正年龄18至24个月接受神经发育检查的婴儿,排除有脑膜炎或严重先天畸形病史者。
- 将极低出生体重儿分为无ROP组、无需治疗的ROP(non-TR-ROP)组和需治疗的ROP(TR-ROP)组。
- 共纳入3132例婴儿,其中1093例(34.9%)患ROP;ROP患儿中644例未治疗(non-TR-ROP组),449例接受ROP治疗(TR-ROP组)。
主要发现
- TR-ROP组较无ROP组发生神经发育问题的风险升高(OR=1.72,95%CI=1.33-2.21)。
- TR-ROP组三类神经发育问题的风险均升高:精神(OR=1.62,95%CI=1.25-2.09)、社交(OR=1.62,95%CI=1.12-2.09)、运动(OR=1.69,95%CI=1.31-2.18)。
- 接受激光治疗的患者与接受抗血管内皮生长因子(anti-VEGF)治疗的患者神经发育问题风险无差异(OR=1.17,95%CI=0.73-1.88)。
关键数值与推荐
- 神经发育障碍定义为根据贝利婴幼儿发展量表第二版(Bayley-II;<70)、贝利婴幼儿发展量表第三版(Bayley-III;<70)、韩国发育筛查测验(K-DST;低于-1 SD)、韩国年龄与阶段问卷(K-ASQ;低于阈值)及粗大运动功能分类系统(GMFCS;2级或以上)评定,存在至少1项发育问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of retinopathy of prematurity (ROP) severity and the treatment of very-low-birth-weight infants (VLBWIs) on neurodevelopmental impairment in early childhood. DESIGN: Prospective cohort study. METHOD: This was a prospective cohort study. The data were obtained from the Korean Neonatal Network (KNN), a nationwide registry for VLBWIs. Infants who were born from 2013 to 2015 and underwent ROP evaluation at birth and neurodevelopmental examinations at corrected ages of 18 to 24 months were included in the study. Infants with a history of meningitis or severe congenital anomalies were excluded. The VLBWI patients were grouped into no ROP, no treatment-requiring ROP (non-TR-ROP), and treatment-requiring ROP (TR-ROP) groups. Neurodevelopmental impairment was defined as participants who had at least 1 developmental problem according to the Bayley Scales of Infant and Toddler Development-2nd Edition (Bayley-II; <70), Bayley Scales of Infant and Toddler Development-3rd Edition (Bayley-III; <70), and Korean Developmental Screening Test (K-DST) tests (below -1 SD), and the Korean Ages and Stages Questionnaire (K-ASQ) (below the threshold) and Gross Motor Function Classification System (GMFCS; at level 2 or above). Multivariable logistic regression analysis was performed to evaluate the association between ROP and neurodevelopmental impairment. RESULT: Among 3132 infants, 1093 (34.9%) had ROP. Among the ROP infants, 644 were not treated for ROP (non-TR-ROP group) and 449 received ROP treatments (TR-ROP group). The patients in the TR-ROP group had an increased risk of developing neurodevelopmental problems compared to those in the no ROP group (odds ratio [OR] = 1.72, 95% CI = 1.33-2.21). The TR-ROP group had a higher risk of all 3 types of neurodevelopmental problems: mental (OR = 1.62, 95% CI = 1.25-2.09), social (OR = 1.62, 95% CI = 1.12-2.09), and motor (OR = 1.69, 95% CI = 1.31-2.18). The risk of neurodevelopmental problems in patients treated with laser therapy did not differ from that in patients treated with anti-vascular endothelial growth factor (anti-VEGF) therapy (OR = 1.17, 95% CI = 0.73-1.88). CONCLUSION: ROP was independently associated with neurodevelopmental impairment in early childhood. The type of ROP treatment (anti-VEGF or laser treatment) did not affect neurodevelopmental impairment in patients in the TR-ROP group.
引用
- Han G, Lim DH, Kang D, et al. Association Between Retinopathy of Prematurity in Very-Low-Birth-Weight Infants and Neurodevelopmental Impairment. Am J Ophthalmol. 2022. PMID: 35998681. doi:10.1016/j.ajo.2022.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。